There’s been significant progress recently in using CRISPR technology to target genetic disorders, particularly in clinical trials for sickle cell disease. Researchers at a prominent university just released results showing an 85% success rate in restoring normal hemoglobin levels in patients. This could be a game changer for biotech companies focusing on gene editing solutions. I’d love to hear thoughts on how this might impact the market landscape.